Table 1 Vaginal colonization with antimicrobial drug-resistant potentially pathogenic gram-negative bacteria among study women in labor
Antibioticsa | Number of the 1472 study women who were colonized with resistant bacteria (prevalence of colonization/proportion of isolates, in %) | |||||||
|---|---|---|---|---|---|---|---|---|
E. coli (n = 504/508)c | K. pneumoniae (n = 144/145) | Enterobacter spp. (n = 32/32) | K. oxytoca (n = 23/23) | Citrobacter spp. (n = 107/107) | Acinetobacter spp. (n = 32/32) | Pseudomonas spp. (n = 3/3) | Proteus spp. (n = 3/3) | |
Ampicillin | 454 (30.8/89.4) | 141 (9.6/97.2) | 31 (2.1/96.9) | 22 (1.5/95.7) | 105 (7.1/98.1) | NA | 0 [6] | 1 (0.1/33.3) |
Amoxycillin-Clavulanic acid | 366 (24.9/72.0) | 120 (8.2/82.8) | 31 (2.1/96.9) | 14 (0.9/60.9) | 80 (5.4/74.8) | NA | NA | 1 (0.1/33.3) |
Trimethoprim-Sulfamethoxazole | 354 (24.0/69.7) | 90 (6.1/62.1) | 17 (1.2/53.1) | 9 (0.6/39.1) | 56 (3.8/52.3) | 21 (1.4/65.6) | NA | 0 [6] |
Ciprofloxacin | 74 (5.0/14.6) | 26 (1.8/17.9) | 3 (0.2/9.4) | 1 (0.1/4.3) | 18 (1.2/16.8) | 9 (0.6/28.1) | 0 [6] | 0 [6] |
Chloramphenicol | 103 (7.0/20.3) | 36 (2.4/24.8) | 5 (0.3/15.6) | 4 (0.3/17.4) | 18 (1.2/16.8) | 4 (0.3/12.5) | 0 [6] | 0 [6] |
Gentamicin | 111 (7.5/21.9) | 37 (2.5/25.5) | 6 (0.4/18.8) | 3 (0.2/13.0) | 22 (1.5/20.6) | 7 (0.5/21.9) | 1 (0.1/33.3) | 0 [6] |
Amikacin | 125 (8.5/24.6) | 33 (2.2/22.8) | 9 (0.6/28.1) | 2 (0.1/8.7) | 19 (1.3/17.8) | 6 (0.4/18.8) | 0 [6] | 0 [6] |
Ceftriaxone | 92 (6.3/18.1) | 42 (2.9/29.0) | 4 (0.3/12.5) | 4 (0.3/17.4) | 31 (2.1/29.0) | NA | NA | 0 [6] |
Cefuroxime | 366 (24.9/72.0) | 92 (6.3/63.4) | 28 (1.9/87.5) | 8 (0.5/34.8) | 83 (5.6/77.6) | NA | NA | 1 (0.1/33.3) |
Ceftazidime | 55 (3.7/10.8) | 30 (2.0/20.7) | 1 (0.1/3.1) | 3 (0.2/13.0) | 7 (0.5/6.5) | 13 (0.9/40.6) | 0 [6] | 0 [6] |
Imipenem | 41 (2.8/8.1) | 19 (1.3/13.1) | 9 (0.6/28.1) | 1 (0.1/4.3) | 27 (1.8/25.2) | 2 (0.1/6.3) | 0 [6] | 0 [6] |
Tetracycline | NA | NA | NA | NA | NA | 9 (0.6/28.1) | 0 [6] | NA |
Piperacillin | NA | NA | NA | NA | NA | 16 (1.1/50.0) | 0 [6] | NA |
Piperacillin-Tazobactam | NA | NA | NA | NA | NA | 11 (0.7/34.4) | 0 [6] | NA |
Colistin | NA | NA | NA | NA | NA | NA | 0 [6] | NA |
ESBL-producing bacteria | 36 (2.4/7.1) | 16 (1.1/11.0) | 1 (0.1/3.1) | 1 (0.1/4.3) | 3 (0.2/2.8) | NA | NA | 0 [6] |
Carbapenem-resistant bacteria | 41 (2.8/8.1) | 19 (1.3/13.1) | 9 (0.6/28.1) | 1 (0.1/4.3) | 27 (1.8/25.2) | 2 (0.1/6.3) | 0 [6] | 0 [6] |
MDR | 426 (28.9/83.9) | 89 (6.0/61.4) | 22 (1.5/68.8) | 6 (0.4/26.1) | 62 (4.2/57.9) | 18 (1.2/56.3) | 2 (0.1/66.7) | 1 (0.1/33.3) |
MDRb | 350 (23.8/68.9) | 54 (3.7/37.2) | 12 (0.8/37.5) | 4 (0.3/17.4) | 32 (2.2/29.9) | 18 (1.2/56.3) | 2 (0.1/66.7) | 1 (0.1/33.3) |